Taipei Exchange - Delayed Quote TWD

TaiwanJ Pharmaceuticals Co., Ltd. (6549.TWO)

Compare
11.45 -0.15 (-1.29%)
At close: June 14 at 2:54 PM GMT+8
Loading Chart for 6549.TWO
DELL
  • Previous Close 11.60
  • Open 11.60
  • Bid 11.35 x --
  • Ask 11.55 x --
  • Day's Range 11.30 - 11.70
  • 52 Week Range 11.30 - 27.00
  • Volume 200,525
  • Avg. Volume 166,726
  • Market Cap (intraday) 882.488M
  • Beta (5Y Monthly) -0.40
  • PE Ratio (TTM) --
  • EPS (TTM) -0.08
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

TaiwanJ Pharmaceuticals Co., Ltd., a specialty pharmaceutical company, develops and commercializes small molecules for chronic organ inflammation of metabolic, autoimmune, and infectious etiologies in Taiwan. The company also develops JKB-122 and JKB-121; and novel chemical entities for therapy to address chronic liver diseases and allergy/asthma. Its products target various diseases that include liver inflammation/liver fibrosis, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, autoimmune diseases, asthma, and atopic dermatitis. The company was incorporated in 2011 and is based in Zhubei, Taiwan.

www.taiwanj.com

12

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 6549.TWO

Performance Overview: 6549.TWO

Trailing total returns as of 6/14/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

6549.TWO
21.03%
TSEC weighted index
25.51%

1-Year Return

6549.TWO
55.88%
TSEC weighted index
30.72%

3-Year Return

6549.TWO
13.58%
TSEC weighted index
30.74%

5-Year Return

6549.TWO
26.01%
TSEC weighted index
113.09%

Compare To: 6549.TWO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 6549.TWO

Valuation Measures

Annual
As of 6/14/2024
  • Market Cap

    867.66M

  • Enterprise Value

    810.00M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    38.15

  • Price/Book (mrq)

    12.96

  • Enterprise Value/Revenue

    35.62

  • Enterprise Value/EBITDA

    -546.33

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -26.59%

  • Return on Assets (ttm)

    -5.39%

  • Return on Equity (ttm)

    -8.73%

  • Revenue (ttm)

    22.74M

  • Net Income Avi to Common (ttm)

    -6.05M

  • Diluted EPS (ttm)

    -0.08

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    58.83M

  • Total Debt/Equity (mrq)

    1.75%

  • Levered Free Cash Flow (ttm)

    2.15M

Research Analysis: 6549.TWO

Company Insights: 6549.TWO

Research Reports: 6549.TWO

People Also Watch